According to estimations of the TMR report, the demand in the global
plasma protease c1-inhibitor treatment market will expand at a strong
20.0% CAGR for the forecast period of 2017 to 2025, for the market to
be evaluated at US$7.9 bn by 2025-end considerably up from its
evaluated worth of US$1.5 bn in 2016. Key vendors in the plasma
protease c1-inhibitor treatment market are engaged in expanding their
product portfolio and expand their distribution networks in order to
penetrate global markets. This has mandated vendors to meet the
regulatory standards set by governing bodies at national and
international level.
Report Overview @
https://www.transparencymarketresearch.com/plasma-protease-c1inhibitor-treatment-market.html
In terms of drug class, the global plasma protease C1-inhibitor
treatment market witness maximum demand from the segment of
c1-inhibitors that led amongst other segments in 2016.
Geography-wise, the report assesses North America to be the most
profitable market for plasma protease c1-inhibitor treatment, which
accounted for a demand worth US$1,510.5 mn in 2017.
Growing investment for innovation in inhibitor drugs, promising
pipeline drugs and novel therapies, and increasing awareness for
hereditary angioedema (HAE) are primarily driving the plasma protease
C1-inhibitor market through 2025.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=33116
One of the key drivers of the plasma protease C1-inhibitor treatment
market is the increasing usage of plasma protease C1-inhibitor
treatment drugs due to the increasing incidence of acute cases of
hereditary angioedema (HAE) and prophylaxis. The emergence of
C1-inhibitor is considered to be a major breakthrough among several
drugs introduced in the plasma protease C1-inhibitor treatment
market. Berinert is a C1-esterase inhibitor for acute HAE that
received approval from the European Union in 2011. Haegarda, which is
derived from C1-esterase inhibitor is approved in the U.S for routine
prophylaxis as a preventive measure against HAE attacks in
adolescents and adults.
Increasing practice of administering prophylactic treatment process
for HAE patient, demand for a new route of administration of
C1-inhibitor drugs, rising demand for administering drugs
subcutaneously among HAE patients are some other growth drivers of
the plasma protease C1-inhibitor treatment market.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33116
Apart from this, commercialization of drugs such as Ruconest in
emerging markets of Asia Pacific is likely to boost the C1-inhibitor
segment in the upcoming years.
Research studies underway for the development of bradykinin B2
receptor antagonist for the treatment of HAE attacks is likely to
propel the global plasma protease C1-inhibitor treatment market. At
present, Firazyr is the only approved bradykinin B2 receptor for the
treatment of acute HAE attack. FR 173657 is another bradykinin B2
receptor that researchers are evaluating for efficacy for acute HAE
attack.
A fresh market intelligence study by Transparency Market Research
(TMR) states that the business landscape of the global plasma
protease c1-inhibitor treatment market is consolidated with intense
competitive rivalry among leading players. TMR detects Shire plc led
the global plasma protease C1-inhibitor treatment market in 2016. Key
factors that account for its dominance are expanded product
portfolio, acquisitions, and widespread market presence. Pharming
Group N.V., CSL Limited, and Sanquin are some other key vendors that
hold significant shares in the overall market for plasma protease
C1-inhibitor treatment.
Purchase this Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=33116<ype=S
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment